This announcement is a separate document:
基石藥業-B：自願公告 - 基石藥業與三生製藥達成Nofazinlimab（抗PD-1單抗）在中國大陸地區的戰略合作及獨家許可協議
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES STRATEGIC PARTNERSHIP AND EXCLUSIVE LICENSING AGREEMENT WITH 3SBIO FOR NOFAZINLIMAB (ANTI-PD-1 ANTIBODY) IN MAINLAND CHINA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.